Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024407 · ClinicalTrials.gov registry record · Phase 1
A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.
A Phase 1 study of Heterotopic Ossification (HO), sponsored by Ashibio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07024407 is a Phase 1 study of Heterotopic Ossification (HO) that is actively recruiting participants, run by Ashibio. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07024407, a Phase 1 study of Heterotopic Ossification (HO), is actively recruiting participants, sponsored by Ashibio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label study of andecaliximab in participants at risk of developing bone where bone should not be, such as in muscle, tendons, and other soft tissues following traumatic spinal cord injury. The goal of this study is to assess the safety of andecaliximab, how much drug is in the body over time (pharmacokinetics/PK), and how it affects the body (pharmacodynamics/PD) in participants who have had a recent traumatic spinal cord injury.
Conditions Studied
Interventions
- DRUG Andecaliximab
Study Locations (1)
Colorado
- Craig Hospital - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07024407
The ClinicalTrials.gov registry entry for NCT07024407 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ashibio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heterotopic Ossification (HO) appearing as the primary indexed condition, and to 1 intervention - of which Andecaliximab is the first listed.
NCT07024407 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT07024407 about?
NCT07024407 is a clinical study titled "A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.". This is an open-label study of andecaliximab in participants at risk of developing bone where bone should not be, such as in muscle, tendons, and other soft tissues following traumatic spinal cord injury. The goal of this study is to assess the safety of andecaliximab, how much drug is in the body o...
What is the current status of trial NCT07024407?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-05-14. Estimated completion is 2026-01.
What conditions does trial NCT07024407 study?
This clinical trial studies the following conditions: Heterotopic Ossification (HO).
What interventions are being tested in trial NCT07024407?
The interventions under investigation include: Andecaliximab (DRUG).
Who is sponsoring clinical trial NCT07024407?
This trial is sponsored by Ashibio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024407 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.